Floatz logo

an9025

Solid Tumors (Phase 1)

Adlai Nortye Biopharma Co., Ltd.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Solid Tumors (Phase 1) cohort.

Asset / SponsorPhaseRating
Lomustine
Proximagen, LLC
Phase 1/2CC
USL-311
Proximagen, LLC
Phase 1/2CC
Arog4-01
Aromics Therapeutics
Phase 1CC
Adce-B05
Adcendo ApS
Phase 1CC
Pembrolizumab
Rondo Therapeutics
Phase 1CC

View all 10 →

Same molecule, other indications

an9025 is also rated in:

RAS MutationDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →